A recent preclinical study of ACC tumors found that several tumors expressed FGFR1 variants that functioned through the AXL/AKT signaling pathway, known to play a role in cancer cell survival and possibly drug resistance [104,105]. This evidence concerns the gene AXL and adrenal cortex carcinoma.